|
Mesothelioma
Treatment
Articles
and Abstracts
Control
of cell cycle progression in human
mesothelioma cells treated with gamma
interferon.
Oncogene
2001 Mar 1;20(9):1085-93
Vivo
C, Levy F, Pilatte Y, Fleury-Feith J,
Chretien P, Monnet I, Kheuang L, Jaurand
MC.
INSERM
E 99.09, Universite Paris Val de Marne
Paris XII (EA 2345), Faculte de Medecine,
8 rue du General Sarrail, 94010, Creteil
Cedex, France.
Recombinant
human interferon gamma (r-hu-IFNgamma)
exerts both antitumoral activity in the
early stages of human malignant
mesothelioma and a cytostatic effect in
human mesothelioma (HM) cell lines in
vitro. The antiproliferative effect of
interferons (IFNs) reported in a variety
of cells has been attributed to several
mechanisms. In order to progress in the
understanding of HM cell growth modulation
by r-hu-IFNgamma, modifications of cell
cycle progression and expression of key
cell cycle regulator proteins in response
to r-hu-IFNgamma were examined. Nine HM
cell lines were studied, including one
resistant to the antiproliferative effect
of r-hu-IFNgamma. Except in the resistant
cell line r-hu-IFNgamma produced an arrest
in the G1 and G2-M phases of the cell
cycle, associated with a reduction in both
cyclin A and cyclin dependent kinase
inhibitors (CDKIs) expression. Moreover
cyclin B1/cdc2 activity was decreased. The
present study provides the first evidence
of a G2-arrest in r-hu-IFNgamma-treated HM
cell lines and indicates that HM cell
lines, despite their tumorigenic origin
still support cell cycle control. The cell
cycle arrest induced by r-hu-IFNgamma
seems to depend on cyclin regulation
through p21(WAF1/CIP1)- and
p27(Kip1)-independent mechanisms and is
not directly related to the induced DNA
damage.
PMID:
11314045 [PubMed - indexed for
MEDLINE]
Click here to order or save
article
If
you have any questions regarding treatment
options or your legal rights, please
contact
us.
|